Database Query Results : , , OPG

OPG, Osteoprotegerin: Click to Expand ⟱
Source:
Type:
Osteoprotegerin (OPG) is a secreted decoy receptor best known for regulating bone remodeling. OPG production in breast cancer cells has been linked to differences in tumor behavior. Some studies suggest that higher OPG expression might counteract RANKL-mediated bone resorption, potentially reducing the risk of bone metastasis.
Prognosis:
-A protective effect has been proposed in certain contexts—elevated OPG levels might be associated with a lower incidence of bone metastasis.
-In contrast, other reports indicate that high circulating OPG levels may correlate with a poorer overall prognosis. This discrepancy could be influenced by whether OPG is functioning in a paracrine fashion within the tumor microenvironment or as a systemic biomarker.
Direction of Regulation in Cancer (Key Point)
Highly context-dependent, with two dominant patterns:
-Upregulated in many tumors and tumor microenvironments
-Function can be protective or tumor-promoting, depending on which pathway dominates

OPG is best viewed as a modulator, not a classical oncogene or tumor suppressor.
Prostate cancer: Often elevated; modulates bone niche

OPG is used as a clinical biomarker

How OPG Is Used as a Biomarker (Reality-Based)

OPG is not a tumor-identity or target-selection biomarker. Its value is contextual and lies in bone and microenvironment assessment.
A) Bone Metastasis Activity (Primary Use)
-What’s measured: Circulating OPG (serum/plasma)
-What it reflects: Host/tumor response to bone remodeling pressure
-Where it matters: Breast cancer, prostate cancer, multiple myeloma
-Clinical use: Prognostic context for skeletal involvement and risk of skeletal-related events (SREs)
-Decision impact: Moderate (supports bone-directed management; not standalone)

B) Tumor Survival Context (Secondary / Interpretive)
-OPG can bind TRAIL, potentially reducing apoptosis of tumor cells.
-Higher OPG may therefore associate with worse outcomes in some cancers despite reduced bone resorption.
-Interpretation requires context (bone disease vs tumor survival predominance).

Often elevated in cancers with bone involvement or inflammatory microenvironments.
Elevation does not imply oncogenic signaling; it reflects niche dynamics.


Scientific Papers found: Click to Expand⟱

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 0

Pathway results for Effect on Cancer / Diseased Cells:


Total Targets: 0

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: OPG, Osteoprotegerin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:1184  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page